Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill
Wall Street Journal
Last updated: May 6, 2026
Novo Nordisk's new pill, Wegovy, has significantly exceeded sales expectations since its launch on January 5th. The drug, developed for weight management, has achieved impressive initial financial results, demonstrating strong market reception.
- Novo Nordisk's Wegovy pill, launched on January 5, 2026, generated $353.6 million in sales. This figure more than doubled the forecast predicted in a Visible Alpha consensus. The strong performance indicates a robust demand for the newly released medication.
- The substantial sales revenue achieved by Wegovy in its initial period highlights its market penetration and the significant interest from consumers and healthcare providers. This early success positions Wegovy as a potentially major product for Novo Nordisk.
